Are uterine leiomyoma a consequence of a chronically inflammatory immune system?

Medical Hypotheses

Volumn 79, Issue 2, 2012, Pages 226-231

  Wegienka, Ganesa ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICAN; AGE DISTRIBUTION; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SURGERY; CARCINOGENESIS; CAUCASIAN; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; HEALTH CARE COST; HUMAN; HYSTERECTOMY; NULLIPARA; PREMENOPAUSE; RACE DIFFERENCE; TH17 CELL; TREATMENT INDICATION; TUMOR IMMUNITY; TUMOR VOLUME; UNITED STATES; UTERUS MYOMA;

CHRONIC DISEASE; CYTOKINES; FEMALE; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LEIOMYOMA; MODELS, IMMUNOLOGICAL; TH17 CELLS; UTERINE NEOPLASMS;

EID: 84863299521     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.04.046     Document Type: Article

References (86)

1. Ross R.K., Pike M.C., Vessey M.P., et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Brit Med J 1986, 293:359-361.
2. Cramer D.W., Patel D. The frequency of uterine leiomyomas. Am J Clin Pathol 1990, 94:435-438.
3. Baird D.D., Dunson D.B., Hill M.C., Cousins D., Schectman J.M. High incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003, 188:100-107.
4. Buttram V.C., Reiter R.C. Uterine leiomyomata: etiology, symptomology, and management. Fertil Steril 1981, 36:433-444.
5. Schwartz S. Invited commentary: studying the epidemiology of uterine leiomyomata - past, present and future. Am J Epidemiol 2001, 153:27-29.
6. Wegienka G., Baird D.D., Hertz-Picciotto I., Harlow S.D., Steege J.F., Schectman J., et al. Self-reported heavy bleeding associated with uterine leiomyomata. Obstet Gynecol 2003, 101(3):431-437.
7. Wegienka G, Baird DD, Hertz-Picciotto I, Harlow SD, Hartmann KE. Uterine leiomyomata (fibroids): are bleeding symptoms more likely to be reported after diagnosis? J Clin Epidemiol 2004.
8. Hartmann K.E., Birnbaum H., Ben-Hamadi R., et al. Annual costs associated with diagnosis of uterine leiomyomata. Obstet Gynecol 2006, 108:930-937.
9. Farquhar C.M., Steiner C.A. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol 2002, 99:229-234.
10. Weiss G., Goldsmith L.T., Taylor R.N., Bellet D., Tayl H.S. Inflammation in reproductive disorders. Reprod Sci 2009, 16:216-229.
11. Modugno F., Ness R.B., Chen C., Weiss M.S. Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomarkers Prev 2005, 14:2840-2847.
12. Mellor A.L., Munn D. Policing pregnancy: Tregs help keep the peace. Trends Immunol 2004, 25:563-565.
13. Abbas AK, Lichtman A. Basic immunology: functions and disorders of the immune system, 1st ed. Philadelphia (PA): W.B. Saunders Company; 2001.
14. Awashti A., Kuchroo V. Th17 cells: from precursor to players in inflammation and infection. Int Immunol 2009, 21:489-498.
15. Petersen A.W., Pedersen B.K. The anti-inflammatory effect of exercise. J Appl Physiol 2005, 98:1154-1162.
16. Santarlasci V., Maggi L., Capone M., et al. TGFβ indirectly favors the development of human Th17 cells by inhibiting Th1 cells. Eur J Immunol 2009, 39:207-215.
17. Baird D.D., Dunson D.B., Hill M.C., Cousins D., Schectman J.M. Association of physical activity with development of uterine leiomyoma. Am J Epidemiol 2007, 165:157-163.
18. Eiser A.R. Does over-expression of transforming growth factor-beta account for the increased morbidity in African-Americans? Possible clinical study and therapeutic implications. J Med Hypoth 2010, 75:418-421.
19. Izcue A., Powrie F. Prenatal tolerance - a role for regulatory T cells?. Eur J Immunol 2005, 35:379-382.
20. Sakaguchi S., Regulatory T. Cells: key controllers of immunologic self-tolerance. Cell 2000, 101:455-458.
21. Somerset D.A., Zheng Y., Kilby M.D., Sansom D.M., Drayson M.T. Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology 2004, 112:38-43.
22. Powrie F., Maloy K.J. Immunology. Regulating the regulators. Science 2003, 299:1030-1031.
23. Murphy K, Travers P, Walport. Janeway's immunobiology, 7th ed. Garland Science; 2008.
24. Faerstein E., Szklo M., Rosenshein N.B. Risk factors for uterine leiomyoma: a practice-based case-control study. II. Atherogenic risk factors and potential sources of uterine irritation. Am J Epidemiol 2001, 153:11-19.
25. Ross R. Atherosclerosis - an inflammatory disease. NEJM 1999, 340:115-126.
26. Sozen I., Arici A. Cellular biology of myomas: interaction of sex steroids with cytokines and growth factors. Obstet Gynecol Clin N Am 2006, 33:41-58.
27. Bischof P. Endocrine, paracrine and autocrine regulation of trophoblastic metalloproteinases. Early Pregnancy 2001, 5:30-31.
28. Bastard J.P., Maachi M., Lagathu C., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4-12.
29. Sikorski R., Kapec E., Zaleska W. Serum levels of proinflammatory cytokines in women with uterine myomas. Ginekol Pol 2001, 72:1485-1488.
30. Gmyrek G.B., Sieradzka U., Goluda M., et al. Flow cytometric evaluation of intracellular cytokine synthesis in peripheral mononuclear cells of women with endometriosis. Immunol Invest 2008, 37:43-61.
31. Gmyrek G.B., Sozanski R., Jerzak M., et al. Evaluation of monocyte chemotactic protein-1 levels in peripheral blood of infertile women with endometriosis. Eur J Obstet Gynecol Reprod Biol 2005, 122:199-205.
32. Kjerulff K.H., Langenberg P., Seidman J.D., Stolley P.D., Guzinski G.M. Uterine leiomyomas: racial differences in severity, symptoms and age at diagnosis. J Reprod Med 1996, 41:483-490.
33. Amant F, Huys E, Geurts Moespot, et al. Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor levels. J Soc Gynecol Invest 2003;10:105-9.
34. Ness R.B., Haggerty C.L., Harger G., Ferrell R. Differential distribution of allelic variants in cytokine genes among African Americans and White Americans. Am J Epidemiol 2004, 160:1033-1038.
35. Wise L.A., Palner J.R., Spiegelmann D., et al. Influence of body size and body fat distribution on risk of uterine leiomyomata in US black women. Epidemiology 2005, 16:346-354.
36. Rocha V.Z., Folco E.J., Sukhova G., et al. Inteferon-γ, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res 2008, 103:467-476.
37. Coppack S.W. Pro-inflammatory cytokines and adipose tissues. Proc Nutr Soc 2001, 60:349-356.
38. Bettelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006, 41(235):238.
39. Tato C.M., O'Shea J.J. What does it mean to be just 17?. Nature 2006, 441:166-168.
40. Ross P.K., Pike M.C., Vessey M.P., et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Brit Med Clin Res Ed 1986, 293:359-362.
41. Romieu I., Walker A.M., Jick S. Determinants of uterine fibroids. Post Mark Surveill 1991, 5:119-133.
42. Lumbiganon P., Rugpao S., Phandhu-fung S., et al. Protective effect of depot-medroxyprogestoerone acetate on surgically treated uterine leiomyomata: a multi-centre case-control study. Brit J Obstet Gynaecol 1996, 103:909-914.
43. Parazzini F., Negri E., La Vecchia C., et al. Uterine myomas and smoking. Results from an Italian study. J Reprod Med 1996, 41:316-320.
44. Faerstein E., Szklo M., Rosenshein N.B. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive hostory, body size, and smoking. Am J Epidemiol 2001, 153:1-10.
45. Marshall L.M., Spiegelman D., Manson J.F., et al. Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking. Epidemiology 1998, 9:511-517.
46. Wise L.A., Palmer J.R., Harlow B.L., et al. Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the Black Women's Health Study. Hum Reprod 2004, 19:1746-1754.
47. Walser T., Cui X., Yanagawa J., et al. Smoking and lung cancer. The role of inflammation. Proc Am Thorac Soc 2008, 5:811-815.
48. Domagala-Kulawik J. Effects of cigarette smoke on the lung and systemic immunity. J Physiol Pharm 2008, 56:19-34.
49. Flouris A.D., Metsios G.S., Carrillo A.E., et al. Acute and short-term effects of secondhand smoke on lung function and cytokine exposure. Am J Resp Crit Care Med 2009, 179:1029-1033.
50. Marshall L.M., Spiegelman D., Goldman M.B., et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998, 70:432-439.
51. Parazzini F., Negri E., Vecchia C.L., Chatenoud L., Ricci E., Guarnerio P. Reproductive factors and risk of uterine fibroids. Epidemiology 1996, 7:440-442.
52. Sato F., Miyake H., Mishi M., Kudo R. Fertility and uterine size among Asian women undergoing hysterectomy for leiomyomas. Int J Fertil 2000, 45:34-37.
53. Baird D.D., Dunson D.B. Why is parity protective for uterine fibroids?. Epidemiology 2003, 14:247-250.
54. Parazzini F., La Vecchia C., Negri E., et al. Epidemiologic characteristics of women with uterine fibroids: a case control study. Obstet Gynecol 1988, 72:853-857.
55. Samadi A.R., Lee N.C., Flanders W.D., Boring J.R., Parris E.B. Risk factors for self-reported uterine fibroids: a case-control study. Am J Public Health 1996, 86:858-862.
56. Pritts E.A., Parker W.H., Olive D.L. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril 2009, 91:1215-1223.
57. Lev-Toaff A.S., Coleman B.G., Arger P.H., Mintz M.C., Arenson R.L., Toaff M.E. Leiomyomas in pregnancy: sonographic study. Radiology 1987, 164:375-380.
58. Aharoni A., Reier A., Golan D., Paltiely Y., Sharf M. Patterns of growth of uterine leiomyomas during pregnancy. A prospective longitudinal study. Brit J Obstet Gynecol 1988, 95:510-513.
59. Rosati P., Exacoustas C., Mancuso S. Longitudinal evaluation of uterine myoma growth during pregnancy: a sonographic study. J Ultrasound Med 1992, 11:511-515.
60. Strobelt N., Ghidini A., Cavallone M., Pensabene I., Ceruti P., Vargani P. Natural history of uterine leiomyomas in pregnancy. J Ultrasound Med 1994, 13:399-401.
61. Piccinni M.P. T-cell cytokines in pregnancy. Am J Reprod Immunol 2002, 47:289-294.
62. Heikkinen J., Mottonen M., Alanen A., Lassila O. Phenotypic characterization of regulatory T cells in the human decidua. Clin Exp Immunol 2004, 2004(136):373-378.
63. O'Garra A., Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004, 2004(10):801-805.
64. Baecher-Allan C., Viglietta V., Hafler D.A. Human CD4+CD25+ regulatory T cells. Semin Immunol 2004, 16:89-98.
65. Cantorna MT, Zhu Y, Froicu, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004;80:1717S-20S.
66. Norman A.W. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 2008, 88(S):491S-499S.
67. Halder S.K., Goodwin J.S., Al-Hendy A. 1,25-Dihydroxyviotamin D3 reduced TGFβ-3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab 2011, 96:E754-E762.
68. Chiaffrina F., Parazzini F., LaVecchia C., et al. Diet and uterine myomas. Obstet Gynecol 1999, 94:395-398.
69. Terry K.L., Missmer S.A., Hankinson S.E., Willett W.C., De Vivo I. Lycopene and other carotenoid intake in relation to risk of uterine leiomyoma. Am J Obstet Gynecol 2008, 198:371-378.
70. Manning P.J., Sutherland W.H., McGrath M.M., et al. Postprandial cytokine concentrations and meal composition in obese and lean women. Obesity 2008, 16:2046-2052.
71. Wise L.A., Radin R.G., Palmer J.R., Kumanyika S.K., Rosenberg L. A prospective study of dairy intake and risk of uterine leiomyomata. Am J Epidemiol 2010, 171:221-232.
72. Radin R.G., Palmer J.R., Rosenberg L., Kumanyika S.K., Wise L.A. Dietary glycemic index in relation to risk of uterine leiomyomata in the Black Women's Health Study. Am J Clin Nutr 2010, 91:1281-1288.
73. Baird D.D., Travlos G., Wilson R., et al. Uterine leiomyomata in relation to insulin-like growth factor-I, insulin and diabetes. Epidemiology 2009, 20:604-610.
74. Bullerdiek J. Leiomyoma - do viruses play the main role?. Genes Chromosomes Cancer 1999, 26:181.
75. Matoba T, Berk BC. Inflammation, cardiovascular disease, and hypertension: molecular mechanisms. In: Molecular mechanisms in hypertension. Informa Healthcare; 2006/2007. p. 335-42.
76. Wise L.A., Palmer J.R., Cozier Y.C., et al. Perceived racial discrimination and risk of uterine leiomyomata. Epidemiology 2007, 18:747-757.
77. Boynton-Jarrett R., Rich-Edwards J.W., Jun H.J., Hibert E.N., Wright R.J. Abuse in childhood and risk of uterine leiomyoma. Epidemiology 2011, 22:6-14.
78. Vines A.I., Ta M., Esserman D.A. The association between self-reported major life events and the presence of uterine fibroids. Women's Health Issues 2010, 20:294-298.
79. Butcher SK, Lord JM. Stress response and innate immunity: aging as a contributory factor. Aging Cell 2004:151-60.
80. Prather A.A., Carroll J.E., Fury J.M., et al. Gender differences in stimulated cytokine production following acute psychological stress. Brain Behav Immun 2009, 23:622-628.
81. Baird D.D. Invited commentary: uterine leiomyomata - we know so little but could learn so much. Am J Epidemiol 1994, 159:124-126.
82. Raetch H., Stewart M.E. Uterine leiomyomas, serum cholesterol, and oral contraceptives. Diag Gynecol Obstet 1982, 4:21-24.
83. Parazzini F., Negri E., La Vecchia C., et al. Oral contraceptive use and risk of uterine fibroids. Obstet Gynecol 1992, 79:430-433.
84. Walnut creek contraceptive drug study. A prospective study of the side effects of oral contraceptives, vol. 3. Bethesda (MD): National Institutes of Health; 1981.
85. Wise L.A., Palmer J.R., Harlow B.L., et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004, 159:113-123.
86. Ness R.B., Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999, 91:1459-1467.